Question
1 – The IKEA Sustainability Strategy states that the company want to
become “Circular and Climate Positive”. The strategy presents ambitions
and commitments in sustainability towards 2030 that affect the company
and its network (listed below). Supported by the articles used in
Seminar 1 and the lectures related to ‘Business Networks and
Relationships’, you need to identify and explain one possible effect of
IKEA’s Sustainability Strategy on its supply chain network (maximum 600
words -the equivalent of 1 page/Font 12/single space)
“By
2030, our ambition is to be a circular business built on clean,
renewable energy and regenerative resources, de-coupling material use
from our growth. The aim is to end our dependency on virgin fossil
materials and fuels. We will reduce greenhouse gases and contribute to
limiting the global temperature increase to 1.5°C by the end of the
century. We will also contribute to a world of clean air and water and
improved biodiversity.
We
are committed to: Continuing to secure and develop responsible sourcing
standards that include environmental, social and animal welfare
criteria. Becoming forest positive, promoting sustainable forest
management to eliminate forest degradation and deforestation. Using
innovative approaches to forest management, protection, restoration, and
regeneration. Sourcing wood, cotton, food, and other raw materials from
more sustainable sources. Providing and promoting services, solutions,
inspiration and offering easy access to knowledge to prolong the life of
product and materials. Inviting and enabling customers and other
partners to be part of the solution by making it easy to buy, fix, sell,
share and give away products.”
Source: IKEA, 2020, n.d.
Question
2 – Using the case provided below, identify and explain the benefits of
the type of network strategy established by Sanofi and GSK to develop
the vaccine. Support your answer by discussing the different network
strategies presented in the articles discussed in the seminar and the
articles from course week 2. (maximum 600 words -the equivalent of 1
page/Font 12/single space)
Case: Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19
PARIS
and LONDON – April 14, 2020 – Sanofi and GSK today announce that they
have signed a letter of intent to develop an adjuvanted vaccine for
COVID-19, using innovative technology from both companies, to help
address the ongoing pandemic.
Sanofi
will contribute its S-protein COVID-19 antigen, which is based on
recombinant DNA technology. This technology has produced an exact
genetic match to proteins found on the surface of the virus, and the DNA
sequence encoding this antigen has been combined into the DNA of the
baculovirus expression platform, the basis of Sanofi’s licensed
recombinant influenza product in the US.
GSK
will contribute its proven pandemic adjuvant technology. The use of an
adjuvant can be of particular importance in a pandemic situation since
it may reduce the amount of vaccine protein required per dose, allowing
more vaccine doses to be produced and therefore contributing to protect
more people.
As
previously announced by Sanofi, the development of the
recombinant-based COVID-19 vaccine candidate is being supported through
funding and a collaboration with the Biomedical Advanced Research and
Development Authority (BARDA), part of the office of the Assistant
Secretary for Preparedness and Response at the U.S. Department of Health
and Human Services. The companies plan to discuss funding support with
other governments and global institutions prioritising global access.
“Strategic
alliances among vaccine industry leaders are essential to make a
coronavirus vaccine available as soon as possible,” says BARDA Director,
Rick A. Bright, Ph.D. “Development of the adjuvanted recombinant-based
COVID-19 vaccine candidate holds the potential to lower the vaccine dose
to provide vaccine to a greater number of people to end this pandemic,
and help the world become better prepared or even prevent future
coronavirus outbreaks.”
The
companies have set up a Joint Task Force, co-chaired by David Loew,
Global Head of Vaccines, Sanofi and Roger Connor, President Vaccines,
GSK. The taskforce will seek to mobilize resources from both companies
to look for every opportunity to accelerate the development of the
candidate vaccine.
Source: https://www.sanofi.com/en/media-room/press-releases/2020/2020-04-14-13-00-00
Last Completed Projects
| topic title | academic level | Writer | delivered |
|---|